semaglutide alzheimer's phase 3 Frontiers Semaglutide Falls Short in Alzheimer's

Both have shown strong results in clinical trials for weight loss

It has been shown to increase fat metabolism, reduce body fat, and increase muscle mass

The impending loss of exclusivity for semaglutide, the active ingredient in Ozempic and Wegovy, in 2026 is poised to transform the anti-obesity medication (AOM) market, particularly in countries like India, China, Canada, Brazil, and Turkey, which represent 40% of the global population and 33% of adults with obesity

The market for such weight-loss treatments, which Novo Nordisk is targeting with anti-obesity treatment Wegovy, is forecast to reach $150 billion by the early 2030s

Learn More about Immunity Response

New Zealand Society for the Study of Diabetes (NZSSD), Ministry of Health